Active Biotech's I-3D Micro-dosing Clinical Trial Concluded ( ecting a lead compound with which to in...)

Active Biotech's I-3D Micro-dosing Clinical Trial Concluded

ecting a lead compound with which to initiate Phase I clinical trials.

Lund, March 13, 2007

Active Biotech AB (publ) Sven Andréasson President and CEO

For further information, please contact: Sven Andréasson, President and CEO, tel. +46 46 19 20 49 Tomas Leanderson, CSO, tel +46 46 19 20 95 Cecilia Hofvander, Manager Corporate Communication, tel. +46 46 19 11 22

Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, the primary indication being renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for SLE and RhuDex® for RA. In addition, the preclinical development of the I-3D project is being conducted in cooperation with Chelsea Therapeutics.

Active Biotech AB (org.nr 556223-9227) P.O. Box 724, SE-220 07 Lund, Sweden Tel +46 46-19 20 00 Fax +46 46-19 20 50

Page: 1 2
Related medicine technology :

1. Controlling the Spread of Healthcare Associated Methicillin Resistant Staphylococcus aureus Requires Active Surveillance
2. Gentiums Defibrotide Seen as Active in Multiple Myeloma
3. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
4. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
5. New Positive Pre-clinical Data for Active Biotechs RA Project I-3D
6. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
7. Fractionated Radioimmunotherapy With (90)Y-epratuzumab in Non-Hodgkins Lymphoma Appears Safe and Active in a Phase I/II Study
8. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
9. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
10. Copaxone Treatment over Two Years after Short Term Induction with Mitoxantrone Provided Sustained Benefits to Active Relapsing-Remitting Multiple Sclerosis Patients
11. Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual Meeting

Post Your Comments:

( ecting a lead compound with which to in...)Active Biotech's I-3D Micro-dosing Clinical Trial Concluded,Health